Tenvir EM

Emtricitabine + Tenofovir disoproxil fumarate)

TENVIR-EM Tablets (Emtricitabine + Tenofovir disoproxil fumarate)

Post treatment acute exacerbation of hepatitis b, and risk of drug resistance with use of tenofovir df/emtricitabine for pre-exposure prophylaxis (PrEP) in undiagnosed early HIV-1 infection

Severe acute exacerbations of hepatitis B (HBV) have been reported in HBV-infected patients who have discontinued tenofovir DF/emtricitabine. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in HBV-infected patients who discontinue tenofovir DF/emtricitabine. If appropriate, initiation of anti-hepatitis B therapy may be warranted (see warnings and precautions).

Tenofovir disoproxil fumarate/emtricitabine used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and periodically (at least every 3 months) during use. Drug-resistant HIV-1 variants have been identified with use of tenofovir disoproxil fumarate/emtricitabine for a PrEP indication following undetected acute HIV-1 infection. Do not initiate tenofovir disoproxil fumarate/emtricitabine for a PrEP if signs or symptoms of acute hiv-1 infection are present unless negative infection status is confirmed (see warnings and precautions).

Tenvir-EM Tablet is a combination medicine used for the treatment of treat human immunodeficiency virus (HIV) infections. This medicine is not a cure for HIV; it only prevents the virus from multiplying in your body. Monitoring of liver function and kidney function may be necessary while receiving this medicine based on the clinical condition. This medicine is not recommended for use in patients less than 12 years of age.